Anebulo Pharmaceuticals, Inc. (ANEB) Stock
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. is headquartered in US.
Anebulo Pharmaceuticals, Inc. (ANEB) stock trades at $0.34 with a market capitalization of $13.72M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.73, reflecting a net loss over the last twelve months, price-to-book of 1.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $3.42, and currently trades 90.1% below its 52-week high.
On profitability, Anebulo Pharmaceuticals, Inc. generates a return on equity (ROE) of -74.58% (negative, reflecting a net loss), return on capital employed of -102.66%.
Official website: www.anebulo.com
Anebulo Pharmaceuticals, Inc. by the numbers, 2020–2025
Between 2020 and 2025 Anebulo Pharmaceuticals, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-8.0M in 2025.
On a trailing twelve-month basis to Dec '25, revenue is $0 and net profit $-8.0M.
Borrowings stand at $0, cash on hand is $9.0M, cash from operations was $-6.0M in the latest year, positive in 0 of the last 6.
Return on equity has averaged -113.1% over five years, and was -66.7% in the most recent year.
The share price itself has compounded at -45.5% a year over five years, -48.8% over three, -79.8% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Anebulo Pharmaceuticals, Inc. (ANEB) — frequently asked questions
What is Anebulo Pharmaceuticals, Inc. (ANEB) stock price today?
Anebulo Pharmaceuticals, Inc. (ANEB) is currently trading at $0.34, up 0% today.
What is ANEB P/E ratio?
Anebulo Pharmaceuticals, Inc.'s P/E ratio is -1.73. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is ANEB return on equity (ROE)?
Anebulo Pharmaceuticals, Inc.'s return on equity (ROE) is -74.58%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Anebulo Pharmaceuticals, Inc.'s market cap?
Anebulo Pharmaceuticals, Inc. has a market capitalization of $13.72M.
Does ANEB pay a dividend?
Anebulo Pharmaceuticals, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does ANEB carry?
Anebulo Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is ANEB's profit margin?
Anebulo Pharmaceuticals, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is ANEB in?
Anebulo Pharmaceuticals, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is ANEB listed on?
Anebulo Pharmaceuticals, Inc. trades on OTC under the ticker ANEB.
What is ANEB's 52-week range?
Over the last year Anebulo Pharmaceuticals, Inc. has traded between $0.01 and $3.42.
Related Healthcare Stocks
Popular Stocks
Screens ANEB currently matches
On the figures above, Anebulo Pharmaceuticals, Inc. passes the filters for 4 of our ready-made screens, among them Penny Stocks, Stocks Under $1, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.